Peptic Ulcer Disease (PUD) is a prevalent condition affecting millions worldwide. The past few years have witnessed significant strides in the understanding and management of this disease. This article provides a comprehensive review of these advancements and current best practices for PUD management.
Recent advancements in PUD management include the use of novel therapeutic agents and improved diagnostic techniques. Proton pump inhibitors (PPIs) and H2 receptor antagonists remain the mainstay of treatment, but recent studies have shown promising results with the use of potassium-competitive acid blockers (P-CABs) as an alternative to PPIs. Furthermore, the development of endoscopic techniques such as endoscopic mucosal resection and endoscopic submucosal dissection have enhanced the diagnostic accuracy and treatment of PUD.
Best practices in PUD management emphasize early diagnosis, appropriate use of pharmacotherapy, and lifestyle modifications. A combination of endoscopy and biopsy is the gold standard for diagnosing PUD. Pharmacotherapy should be individualized and typically involves PPIs or H2 receptor antagonists, along with eradication of Helicobacter pylori if present. Lifestyle modifications include dietary changes, stress management, and cessation of smoking and alcohol consumption.
Future directions in PUD management include the development of more effective and safer therapeutic agents, and implementation of precision medicine. The use of artificial intelligence in predicting disease course and response to treatment is an emerging field of interest. Additionally, the role of microbiome in PUD pathogenesis and treatment is currently under investigation.
In conclusion, the management of PUD has significantly evolved over the years, with advancements in therapeutic agents and diagnostic techniques, and emphasis on individualized treatment and lifestyle modifications. There is a need to keep abreast with these developments for optimal patient care. Future research should focus on developing safer and more effective treatment modalities, and exploring the role of precision medicine and microbiome in PUD management.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation